Kezar Life Sciences (NASDAQ:KZR) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Kezar Life Sciences (NASDAQ:KZR) announced its quarterly earnings results on Tuesday. The company reported ($2.77) EPS for the quarter, missing the consensus estimate of ($2.71) by ($0.06), Zacks reports.

Kezar Life Sciences Trading Down 8.4 %

Shares of KZR stock opened at $5.64 on Wednesday. Kezar Life Sciences has a 12 month low of $5.20 and a 12 month high of $9.53. The company has a market cap of $41.15 million, a PE ratio of -0.43 and a beta of 0.49. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $6.07 and its two-hundred day moving average is $6.71.

Analyst Ratings Changes

KZR has been the subject of several recent research reports. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th. Wells Fargo & Company decreased their price objective on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, December 19th. Finally, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.